Vas Narasimhan wants No­var­tis to have a big fo­cus on Chi­na. Here’s what that looks like

As Chi­na se­cures a spot in every multi­na­tion­al phar­ma gi­ant CEO’s mind with its enor­mous mar­ket and rapid reg­u­la­to­ry re­forms, No­var­tis’ Vas Narasimhan is ready to set clear goals

Brief­ing in­vestors on an earn­ings call, Narasimhan mapped out one of the most de­tailed cas­es for ramp­ing up sales of new drugs in Chi­na. Re­it­er­at­ing a goal to score 50 NDA ap­provals be­tween 2020 and 2024, he notes:

That’s a dou­bling of the rate we’ve had over re­cent years, and our goal is to de­liv­er greater than 90% of our 2024 and be­yond Chi­na sub­mis­sions si­mul­ta­ne­ous­ly with glob­al sub­mis­sions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER